Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials

Ren, Ke; Hamdy, Hayam; Meyiah, Abdo; Elkord, Eyad

doi:10.3389/fimmu.2024.1501613

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials

Ren, Ke; Hamdy, Hayam; Meyiah, Abdo; Elkord, Eyad

Authors

Ke Ren

Hayam Hamdy

Abdo Meyiah

Eyad Elkord

Abstract

Lymphocyte-activation gene 3 (LAG-3) has emerged as a key immune checkpoint regulating immune responses in the context of cancer. The inhibitory effect of LAG-3-expressing T cells contributes to suppressing anti-tumor immunity and promoting tumor progression. This review discusses the function of LAG-3 in immune suppression, its interactions with ligands, and its potential as a prognostic biomarker for cancers. We also explore therapeutic strategies targeting LAG-3, including monoclonal antibodies, small molecule inhibitors, and CAR T cells. This review summarizes the current preclinical and clinical studies on LAG-3, highlighting the potential of therapeutic regimens targeting LAG-3 to enhance antitumor immunity and improve patients’ outcomes. Further studies are needed to fully elucidate the mechanism of action of LAG-3 and optimize its application in tumor therapy.

Citation

Ren, K., Hamdy, H., Meyiah, A., & Elkord, E. (in press). Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials. Frontiers in Immunology, 15, 1501613. https://doi.org/10.3389/fimmu.2024.1501613

Journal Article Type	Article
Acceptance Date	Nov 7, 2024
Online Publication Date	Nov 26, 2024
Deposit Date	Jan 15, 2025
Publicly Available Date	Jan 15, 2025
Journal	Frontiers in Immunology
Electronic ISSN	1664-3224
Publisher	Frontiers Media
Peer Reviewed	Peer Reviewed
Volume	15
Pages	1501613
DOI	https://doi.org/10.3389/fimmu.2024.1501613
Keywords	T cells, biomarker, LAG-3, immune checkpoint, cancer

Files

Published Version (2.6 Mb)
PDF

Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/

Copyright Statement
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.